Honestly, I don't like to speculate on such matters. All I can say is that based on the projected revenue stream for LymPro after FDA approval, it should generate a sale price equal to or higher than the $800M Eli Lilly paid for Amyvid in their acquisition of Avid Radiopharmaceuticals. How much higher is anyone's guess. There is also the possibility of earning a percentage of the revenue stream from the buyer.

Since GC mentioned a bidding war in the recent business update call, it seems reasonable to conclude the sale of LymPro or the entire diagnostics division is certainly an option they are considering at some point.
.